相似文献
1
Similarities and perspectives on the two C's-Cancer and COVID-19.对两个“C”——癌症和 COVID-19 的相似性和观点。
J Thromb Haemost. 2021 May;19(5):1161-1167. doi: 10.1111/jth.15294. Epub 2021 Mar 31.
2
Thrombosis, cancer, and COVID-19.血栓形成、癌症和 COVID-19。
Support Care Cancer. 2022 Oct;30(10):8491-8500. doi: 10.1007/s00520-022-07098-z. Epub 2022 May 14.
3
[Coagulopathies, thrombotic risk and anticoagulation in COVID-19].[新型冠状病毒肺炎中的凝血功能障碍、血栓形成风险与抗凝治疗]
Rev Med Liege. 2020;75(S1):86-93.
4
Pathomechanisms Underlying Hypoxemia in Two COVID-19-Associated Acute Respiratory Distress Syndrome Phenotypes: Insights From Thrombosis and Hemostasis.两种 COVID-19 相关急性呼吸窘迫综合征表型低氧血症的发病机制：血栓形成和止血的见解。
Shock. 2022 Jan 1;57(1):1-6. doi: 10.1097/SHK.0000000000001825.
5
Clinical trials and the COVID-19 pandemic.临床试验与新冠疫情
Hell J Nucl Med. 2020 Jan-Apr;23(1):4-5. doi: 10.1967/s002449912014.
6
Are children with SARS-CoV-2 infection at high risk for thrombosis? Viscoelastic testing and coagulation profiles in a case series of pediatric patients.儿童感染 SARS-CoV-2 是否有发生血栓的高风险？儿童患者病例系列中的黏弹性检测和凝血特征。
Pediatr Blood Cancer. 2020 Dec;67(12):e28737. doi: 10.1002/pbc.28737.
7
Pulmonary embolism during SARS-CoV-2 pandemic: Clinical and radiological features.严重急性呼吸综合征冠状病毒 2 流行期间的肺栓塞：临床和影像学特征。
Rev Clin Esp (Barc). 2022 Jun-Jul;222(6):354-358. doi: 10.1016/j.rceng.2021.01.004. Epub 2021 Jun 12.
8
COVID-19 and Peripheral Artery Thrombosis: A Mini Review.COVID-19 与外周动脉血栓形成：小型综述。
Curr Probl Cardiol. 2022 Oct;47(10):100992. doi: 10.1016/j.cpcardiol.2021.100992. Epub 2021 Sep 24.
9
COVID-19: progression of disease and intravascular coagulation - present status and future perspectives.COVID-19：疾病进展与血管内凝血——现状与未来展望。
Clin Chem Lab Med. 2020 Jun 25;58(7):1029-1036. doi: 10.1515/cclm-2020-0502.
10
Systemic inflammation in COVID-19 patients may induce various types of venous and arterial thrombosis: A systematic review.新型冠状病毒肺炎患者的全身炎症可能会引发各种类型的静脉和动脉血栓形成：系统评价。
Scand J Immunol. 2021 Nov;94(5):e13097. doi: 10.1111/sji.13097. Epub 2021 Sep 27.
引用本文的文献
1
Venous thromboembolism risk, prophylaxis and management in cancer patients with COVID-19: An unmet medical need.COVID-19癌症患者的静脉血栓栓塞风险、预防与管理：一项未满足的医疗需求。
Thromb Update. 2022 Mar;6:100098. doi: 10.1016/j.tru.2022.100098. Epub 2022 Jan 10.
2
Continuous care needs in patients with cancer receiving chemotherapy during the recent omicron wave of COVID-19 in Shanghai: A qualitative study.上海新冠疫情奥密克戎毒株流行期间接受化疗的癌症患者的持续护理需求：一项定性研究
Front Psychol. 2023 Jan 4;13:1067238. doi: 10.3389/fpsyg.2022.1067238. eCollection 2022.
3
Haematological predictors of poor outcome among COVID-19 patients admitted to an intensive care unit of a tertiary hospital in South Africa.南非一家三级医院重症监护病房的 COVID-19 患者预后不良的血液学预测因子。
PLoS One. 2022 Nov 4;17(11):e0275832. doi: 10.1371/journal.pone.0275832. eCollection 2022.
4
Thrombotic and bleeding complications in patients with chronic lymphocytic leukemia and severe COVID-19: a study of ERIC, the European Research Initiative on CLL.慢性淋巴细胞白血病合并重症 COVID-19 患者的血栓和出血并发症：ERIC 研究，即欧洲慢性淋巴细胞白血病研究倡议。
J Hematol Oncol. 2022 Aug 26;15(1):116. doi: 10.1186/s13045-022-01333-0.
5
Thrombosis, cancer, and COVID-19.血栓形成、癌症和 COVID-19。
Support Care Cancer. 2022 Oct;30(10):8491-8500. doi: 10.1007/s00520-022-07098-z. Epub 2022 May 14.
6
Lessons learnt from COVID-19 coagulopathy.从新冠病毒相关凝血病中吸取的教训。
EJHaem. 2021 May 17;2(3):577-584. doi: 10.1002/jha2.228. eCollection 2021 Aug.
本文引用的文献
1
D-Dimers Level as a Possible Marker of Extravascular Fibrinolysis in COVID-19 Patients.D-二聚体水平作为新冠病毒肺炎患者血管外纤维蛋白溶解的潜在标志物
J Clin Med. 2020 Dec 24;10(1):39. doi: 10.3390/jcm10010039.
2
Squeezing through the microcirculation: survival adaptations of circulating tumour cells to seed metastasis.挤过微循环：循环肿瘤细胞播种转移的生存适应。
Br J Cancer. 2021 Jan;124(1):58-65. doi: 10.1038/s41416-020-01176-x. Epub 2020 Dec 1.
3
Dosing of thromboprophylaxis and mortality in critically ill COVID-19 patients.危重症 COVID-19 患者的血栓预防剂量与死亡率。
Crit Care. 2020 Nov 23;24(1):653. doi: 10.1186/s13054-020-03375-7.
4
Breakthrough venous thromboembolic events in five patients with COVID-19 on direct oral anticoagulants.五例 COVID-19 患者使用直接口服抗凝剂后出现突破性静脉血栓栓塞事件。
J Clin Pharm Ther. 2021 Apr;46(2):519-523. doi: 10.1111/jcpt.13311. Epub 2020 Nov 20.
5
Incidence, risk factors, and outcomes of venous and arterial thromboembolism in immune checkpoint inhibitor therapy.免疫检查点抑制剂治疗中静脉和动脉血栓栓塞的发生率、风险因素和结局。
Blood. 2021 Mar 25;137(12):1669-1678. doi: 10.1182/blood.2020007878.
6
High rates of pulmonary artery occlusions in COVID-19. A meta-analysis.COVID-19 患者肺动脉闭塞发生率较高。一项荟萃分析。
Eur J Clin Invest. 2021 Jan;51(1):e13433. doi: 10.1111/eci.13433. Epub 2020 Oct 31.
7
Lung Histopathology in Coronavirus Disease 2019 as Compared With Severe Acute Respiratory Sydrome and H1N1 Influenza: A Systematic Review.新型冠状病毒病 2019 与严重急性呼吸综合征和 H1N1 流感的肺部组织病理学比较：系统综述。
Chest. 2021 Jan;159(1):73-84. doi: 10.1016/j.chest.2020.09.259. Epub 2020 Oct 7.
8
ISTH DIC subcommittee communication on anticoagulation in COVID-19.ISTH DIC 小组委员会关于 COVID-19 抗凝治疗的沟通。
J Thromb Haemost. 2020 Sep;18(9):2138-2144. doi: 10.1111/jth.15004.
9
The need for accurate D-dimer reporting in COVID-19: Communication from the ISTH SSC on fibrinolysis.COVID-19中准确D-二聚体报告的必要性：国际血栓与止血学会纤溶专业委员会的沟通
J Thromb Haemost. 2020 Sep;18(9):2408-2411. doi: 10.1111/jth.14956.
10
The Anticoagulant and Nonanticoagulant Properties of Heparin.肝素的抗凝和非抗凝特性。
Thromb Haemost. 2020 Oct;120(10):1371-1383. doi: 10.1055/s-0040-1715460. Epub 2020 Aug 20.
Zotero 插件